Nevro (NVRO) Stock Price, News & Analysis

Company Overview

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $5.71 to $5.75
• 50-Day Range: $3.28 to $5.73
• 52-Week Range: $3.16 to $17.75
• Volume: 1.86 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $214.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.43
• Consensus Rating: Reduce

Nevro Stock Analysis - MarketRank™

Nevro scored higher than 35% of companies evaluated by MarketBeat, and ranked 714th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Nevro has received a consensus rating of Reduce. The company's average rating score is 1.93, and is based on 1 buy rating, 11 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Nevro has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nevro are expected to decrease in the coming year, from ($2.43) to ($2.51) per share.

Price to Book Value per Share Ratio

Nevro has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.58% of the outstanding shares of Nevro have been sold short.

Short Interest Ratio / Days to Cover

Nevro has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Nevro has recently increased by 3.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nevro does not currently pay a dividend.

Dividend Growth

Nevro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.58% of the outstanding shares of Nevro have been sold short.

Short Interest Ratio / Days to Cover

Nevro has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Nevro has recently increased by 3.27%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.49

News Sentiment

Nevro has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Nevro this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for NVRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nevro to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nevro insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Nevro is held by insiders.

Percentage Held by Institutions

95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVRO Stock Analysis - Frequently Asked Questions

How have NVRO shares performed this year?

Nevro's stock was trading at $3.72 on January 1st, 2025. Since then, NVRO stock has increased by 53.7% and is now trading at $5.7160.
View the best growth stocks for 2025 here.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its quarterly earnings results on Monday, November, 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.40. Nevro's revenue was down 7.0% on a year-over-year basis.

Who are Nevro's major shareholders?

Nevro's top institutional shareholders include Assenagon Asset Management S.A. (1.79%), Charles Schwab Investment Management Inc. (0.84%), Raymond James Financial Inc. (0.21%) and Norden Group LLC (0.06%). Insiders that own company stock include Kashif Rashid, Shawn Mccormick and D Keith Grossman.
View institutional ownership trends.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 2/10/2025
• Next Earnings (Estimated): 2/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVRO
• CUSIP: N/A
• CIK: 1444380
• Web: www.nevro.com
• Phone: (650) 251-0005
• Fax: N/A
• Employees: 1,215
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.43
• High Stock Price Target: $16.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +12.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,210,000.00
• Net Margins: -16.54%
• Pretax Margin: -17.89%
• Return on Equity: -23.52%
• Return on Assets: -10.83%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 5.02
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $419.15 million
• Price / Sales: 0.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.10 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 37,472,000
• Free Float: 36,273,000
• Market Cap: $214.19 million
• Optionable: Optionable
• Beta: 0.91